Use combined 5-HT1A agonists and selective serotonin reuptake inhibitors

US7479492B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Gerd Bartoszyk · Weiterstadt, DE
• Ewen Sedman · Alresford, GB

Key dates

• Filing date: Nov 2, 2001
• Grant date: Jan 20, 2009
• Expiry date: Sep 14, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT1A receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain disorders or in treating other conditions where there is hyper-sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain, as well as for the treatment of irritable bowel syndrome (IBS).